Key result
Universal lipid screening at 10 or 18 years of age with genetic testing for familial hypercholesterolemia was not cost-effective, with the best strategy costing $289,700 per QALY gained.
Why the study?
Does universal low-density lipoprotein cholesterol (LDL-C) screening at 10 or 18 years of age improve cost per quality-adjusted life-years (QALYs) in a hypothetical cohort of 4.2 million 10-year-olds in the US?
Does universal low-density lipoprotein cholesterol (LDL-C) screening at 10 or 18 years of age improve cost per quality-adjusted life-years (QALYs) in a hypothetical cohort of 4.2 million 10-year-olds in the US?
No takes yet. Share an insight, caveat, or question.
Universal lipid screening at 10 or 18 years of age with genetic testing for familial hypercholesterolemia is not cost-effective for reducing cardiovascular disease, challenging current professional society recommendations.
A 2026 study studied Familial hypercholesterolemia (n=4,200,000). Universal lipid screening at 10 or 18 years of age with genetic testing for FH vs. Current usual care (age- and sex-specific screening strategies with no universal FH screening) was evaluated on Cost per quality-adjusted life-year (QALY) gained. Universal lipid screening at 10 or 18 years of age with genetic testing for familial hypercholesterolemia was not cost-effective, with the best strategy costing $289,700 per QALY gained.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: